CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

Rhea-AI Summary

CASI Pharmaceuticals (NASDAQ:CASI) will participate at the Guggenheim Healthcare Innovation Conference 2025. The CASI management team is scheduled for a fireside chat on November 12, 2025 at 9:30 AM ET in Boston, MA.

The company noted its focus on CID-103, an investigational anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. CASI also said it will hold one-on-one investor meetings during the conference.

News Market Reaction – CASI

-4.32%

1 alert

-4.32% News Effect

On the day this news was published, CASI declined 4.32%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that the CASI management team will participate at the Guggenheim Healthcare Innovation Conference 2025 in a fireside chat at 9:30 AM ET on November 12 in Boston, MA. CASI will also host one-on-one meetings with investors at the conference.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. and plans for first patient in first quarter of 2026. In parallel, CASI is actively recruiting and dosing patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP). In addition, CASI is assessing multiple technologies for development of a stable, high concentration protein solution for subcutaneous injection.

More information on CASI is available at www.casipharmaceuticals.com.

INVESTOR CONTACT:

Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com

SOURCE: CASI Pharmaceuticals

View the original press release on ACCESS Newswire

FAQ

When will CASI (NASDAQ:CASI) present at the Guggenheim Healthcare Innovation Conference 2025?

CASI will present in a fireside chat on November 12, 2025 at 9:30 AM ET in Boston, MA.

What will CASI management discuss at the November 12, 2025 Guggenheim conference?

The management team will discuss company developments and its clinical-stage program, including CID-103.

Will CASI (CASI) meet investors at the Guggenheim Healthcare Innovation Conference 2025?

Yes. CASI will host one-on-one meetings with investors during the conference.

What is CID-103 that CASI will reference at the Guggenheim conference?

CID-103 is CASI's investigational anti-CD38 monoclonal antibody candidate for organ transplant rejection and autoimmune diseases.

Where is the Guggenheim Healthcare Innovation Conference 2025 session with CASI being held?

The fireside chat is scheduled in Boston, MA on November 12, 2025.

How can investors access CASI's presentation at the Guggenheim Healthcare Innovation Conference 2025?

Investors should check conference schedules and CASI investor relations for availability; CASI indicated management will appear on November 12, 2025.